Mortgage borrowers could face a tougher time and higher interest rates after the Commonwealth Bank of Australia (ASX: CBA) announced plans to increase its ownership of Aussie Home Loans from 33% to 80% late last year.
'Aussie John' Symond will continue as executive chairman of the group and the company will remain a standalone mortgage broker and financial services provider.
Many commentators have expressed concerns that the big four banks have a stranglehold on the Australian mortgage market with estimates they control more than 80%, and this move will likely increase their market share.
Other players have moved to wrestle some of the market share away from the big four, such as Mark Bouris' Yellow Brick Road Holdings (ASX: YBR) deal with Macquarie Group (ASX: MQG) to utilise Macquarie's balance sheet to lend funds to home borrowers.
Yellow Brick Road is aiming to undercut the banks' standard variable rates by offering a 1.15% discount off the base rate of 6.65% on residential home loan products for the first twelve months of the loan. The company will then offer a further guaranteed discount for the life of the loan.
Whether it will be a successful move is difficult to ascertain.
Mortgage borrowers tend to stay with their existing lenders, despite being able to save thousands if they switched to cheaper providers. Moves by the government to make it easier for borrowers to switch lenders have had little effect, and the big four, including the Commonwealth Bank, ANZ Banking Group (ASX: ANZ), Westpac (ASX: WBC) and National Australia Bank (ASX: NAB) have steadily increased their market share since the global financial crisis.
That's also despite them passing on a fraction of the Reserve Bank of Australia's recent rate cuts in full to their customers, unlike some smaller lenders such as ING Direct.
The Foolish bottom line
The domination of the Australian mortgage market by the big four banks looks set to continue. Only further government intervention appears likely to have any chance of changing the current status quo.
Looking to add a little growth to your portfolio? We've just released our "Top 2 Biotechs to Buy Now." These two companies — each with potential blockbuster drugs in the pipeline — could create untold wealth for early investors. Will you be one of them? Click here for this brand-new FREE report.
More reading
- Big four banks take strangehold on mortgages
- QR National chugs on
- Qantas' aggressive Asian push
- Last throw of the dice for Ten?
- New airport back on the agenda
Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned. The Motley Fool's purpose is to help the world invest, better. Take Stock is The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Click here now to request your free subscription, whilst it's still available. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
